Last reviewed · How we verify
Ceramides
At a glance
| Generic name | Ceramides |
|---|---|
| Sponsor | Peking University First Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Skin Barrier Function and Inflammation in Aging: The BIA Study (PHASE4)
- A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer (PHASE1, PHASE2)
- Ceramide Containing Multivesicular Emulsion Application . . . (NA)
- Validation of Skin Instrumentation to Detect Ceramide-Driven Lipid Replenishment - Assessing Skin Glow, Hydration, Trans Epidermal Water Loss, Skin Surface Assessment, Sebum and Least-Reflection Factor. (NA)
- Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (PHASE1)
- Metronidazole SC Penetrance With Moisturizers (NA)
- Evaluation of Serum Ceramides C16, C24, and Sphingosine-1-Phosphate (S1P) in Patients With Acne Vulgaris
- Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ceramides CI brief — competitive landscape report
- Ceramides updates RSS · CI watch RSS
- Peking University First Hospital portfolio CI